Criblage de fragments
Nous utilisons des techniques avancées de RMN pour analyser avec précision les interactions des petites molécules.
⦾ Bibliothèques de dépistage sur mesure
⦾ 50 ans d'expérience dans la découverte de médicaments
⦾ Équipe d'assistance dédiée
⦾ Analyse complète des données
NMX Research and Solutions offers comprehensive services tailored to accelerating drug discovery, particularly focusing on Fragment-Based Drug Discovery (FBDD) by NMR and other orthogonal methods. NMX utilizes its FBDD Platform that integrates NMX's proprietary curated libraries with NMR and other biophysical technologies.
NMR-Based Target Enablement
NMX assesses intrinsic parameters like protein folding, stability, multimeric state, and promiscuity using NMR experiments and other biophysical approaches to ensure the target's suitability for NMR screening and binding assays.
Fragment Screening Using Curated Libraries
NMX uses proprietary, tailored screening libraries which have been experimentally curated to exclude aggregating agents and to ensure compounds possess optimal aqueous solubility, purity, and structural consistency. Additionally, fragments are intelligently pooled to enhance throughput, thereby facilitating rapid identification and characterization of hits from fragment libraries. This dual focus on quality and and efficiency supports our streamlined approach to discovering high quality chemical matter.
Ligand Binding Studies
NMX uses NMR experiments to characterize binding interactions between ligand and disease target. To enhance the validation of these measurements, NMX also employs orthogonal biophysical methods, such as Microscale Thermophoresis (MST), Isothermal Titration Calorimetry (ITC), and Differential Scanning Fluorometry (DSF/nDSF).
Binding Affinity Determination
Binding affinity (KD) are measured by NMR experiments, and other orthogonal biophysical techniques, aiding in the quantitative assessment of ligand target interactions.
Structure-Based Drug Design
NMX employs NMR data alongside computational drug discovery and X-ray crystallography approaches to optimize compounds for specific targets. They also perform binding site determination through various NMR techniques, like chemical shift mapping and competition assays, to refine drug design based on the Structure-Activity Relationship (SAR).
Characterization of Compound Solution Behaviour
NMX monitors compound solution behaviour to avoid common drug discovery artifacts like aggregation and limited solubility. NMX has developed proprietary software and methods to streamline this process, which aids in prioritizing ligands for further evaluation.
Publications sur le criblage de fragments